Intralesional nivolumab may be effective against precancerous oral lesions, Phase I trial results indicate

Injecting nivolumab (Opdivo) directly into precancerous oral lesions led to a reduction in lesion size and allowed some patients to avoid surgery, according to research from a Phase I clinical trial presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17–22.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup